MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ARK Innovation ETF

Direxion Daily S&P Biotech Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Gold Miners Bear 3X ETF

Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

VS TR -1x Short VIX Futures ETF

MicroSectors Gold Miners 3X Leveraged ETN

VS TR 2x Long VIX Futures ETF

Direxion Daily S&P Biotech Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Gold Miners Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Small Cap Bear 3X ETF

Direxion Financial Bear 3X Shar

Archer Aviation Inc. Class A Common Stock

AgEagle Aerial Systems Inc. Common Stock

ChargePoint Holdings Inc. Common Stock

Dana Incorporated Common Stock

Reddit Inc. Class A Common Stock

Hims & Hers Health Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Oklo Inc.

Northern Oil and Gas Inc. Common Stock

Noble Corporation plc A Ordinary Shares

Endeavour Silver Corporation Ordinary Shares (Canada)

Agnico Eagle Mines Limited Common Stock

Gold Fields Limited American Depositary Shares

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Hilton Grand Vacations Inc. Common Stock

New Gold Inc.

Eldorado Gold Corporation Ordinary Shares

Hecla Mining Company Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Century Communities Inc. Common Stock

Click here to get full coverage on Mediar commences dosing in Phase II trial of MTX-463 for IPF - Clinical Trials Arena

Mediar commences dosing in Phase II trial of MTX-463 for IPF  Clinical Trials Arena

Mediar commences dosing in Phase II trial of MTX-463 for IPF - Clinical Trials Arena

Click here to get full coverage on Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis - PR Newswire

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis  PR Newswire

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis - PR Newswire

Click here to get full coverage on Short Interest in Minerals Technologies Inc. (NYSE:MTX) Rises By 19.0% - MarketBeat

Short Interest in Minerals Technologies Inc. (NYSE:MTX) Rises By 19.0%  MarketBeat

Short Interest in Minerals Technologies Inc. (NYSE:MTX) Rises By 19.0% - MarketBeat

Click here to get full coverage on MTX Group acquires public sector IT consultancy Stralto - Consulting.us

MTX Group acquires public sector IT consultancy Stralto  Consulting.us

MTX Group acquires public sector IT consultancy Stralto - Consulting.us

Click here to get full coverage on MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025 - Pulmonary Fibrosis News

MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025  Pulmonary Fibrosis News

MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025 - Pulmonary Fibrosis News

Click here to get full coverage on Dividend Alert: Minerals Technologies Confirms Next $0.11 Payout for June 2025 - Stock Titan

Dividend Alert: Minerals Technologies Confirms Next $0.11 Payout for June 2025  Stock Titan

Dividend Alert: Minerals Technologies Confirms Next $0.11 Payout for June 2025 - Stock Titan

Click here to get full coverage on Should You Investigate MTU Aero Engines AG (ETR:MTX) At €344? - Yahoo Finance

Should You Investigate MTU Aero Engines AG (ETR:MTX) At €344?  Yahoo Finance

Should You Investigate MTU Aero Engines AG (ETR:MTX) At €344? - Yahoo Finance

Click here to get full coverage on MTX Group Acquires Stralto - citybiz

MTX Group Acquires Stralto - citybiz

Click here to get full coverage on Secretary of state spending includes millions in no-bid contracts - Indiana Capital Chronicle

Secretary of state spending includes millions in no-bid contracts  Indiana Capital Chronicle

Secretary of state spending includes millions in no-bid contracts - Indiana Capital Chronicle

Click here to get full coverage on Minerals Technologies Inc. (NYSE:MTX) Stake Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Minerals Technologies Inc. (NYSE:MTX) Stake Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC  MarketBeat

Minerals Technologies Inc. (NYSE:MTX) Stake Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Click here to get full coverage on Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts? - Yahoo Finance

Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts?  Yahoo Finance

Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts? - Yahoo Finance

Click here to get full coverage on Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment - Clinical Trials Arena

Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment  Clinical Trials Arena

Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment - Clinical Trials Arena

Click here to get full coverage on Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan - Stock Titan

Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan  Stock Titan

Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan - Stock Titan

Click here to get full coverage on MTU Aero Engines (ETR:MTX) Stock Price Down 0.2% - Should You Sell? - MarketBeat

MTU Aero Engines (ETR:MTX) Stock Price Down 0.2% - Should You Sell?  MarketBeat

MTU Aero Engines (ETR:MTX) Stock Price Down 0.2% - Should You Sell? - MarketBeat

Click here to get full coverage on Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)  PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire

Click here to get full coverage on Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds - Yahoo Finance

Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds  Yahoo Finance

Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds - Yahoo Finance

Click here to get full coverage on Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg - PR Newswire

Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg  PR Newswire

Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg - PR Newswire

Click here to get full coverage on Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government - PR Newswire

Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government  PR Newswire

Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government - PR Newswire

Click here to get full coverage on Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress® - PR Newswire

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®  PR Newswire

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress® - PR Newswire

Click here to get full coverage on Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance

Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...  Yahoo Finance

Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance

Click here to get full coverage on (MTX) Long Term Investment Analysis - news.stocktradersdaily.com

(MTX) Long Term Investment Analysis  news.stocktradersdaily.com

(MTX) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ... - Yahoo Finance

Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ...  Yahoo Finance

Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ... - Yahoo Finance

Click here to get full coverage on Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings - Nasdaq

Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings  Nasdaq

Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings - Nasdaq

Click here to get full coverage on HD-MTX Found Safe and Effective for Younger Patients With PCNSL - Oncology Nurse Advisor

HD-MTX Found Safe and Effective for Younger Patients With PCNSL  Oncology Nurse Advisor

HD-MTX Found Safe and Effective for Younger Patients With PCNSL - Oncology Nurse Advisor

Click here to get full coverage on Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates - Nasdaq

Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates  Nasdaq

Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates - Nasdaq

Click here to get full coverage on Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases - Frontiers

Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases  Frontiers

Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases - Frontiers

Click here to get full coverage on Is Minerals Technologies Inc. (MTX) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Is Minerals Technologies Inc. (MTX) The Most Undervalued Stock With Smart Money Ratings?  Insider Monkey

Is Minerals Technologies Inc. (MTX) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Click here to get full coverage on New DeFi Token $MTX Gains Attention Among Cardano Community Amid Exchange Launch Plans - The Tribune

New DeFi Token $MTX Gains Attention Among Cardano Community Amid Exchange Launch Plans  The Tribune

New DeFi Token $MTX Gains Attention Among Cardano Community Amid Exchange Launch Plans - The Tribune

Click here to get full coverage on Lilly Makes $780M+ IPF Play with Mediar Partnership - BioSpace

Lilly Makes $780M+ IPF Play with Mediar Partnership  BioSpace

Lilly Makes $780M+ IPF Play with Mediar Partnership - BioSpace

Click here to get full coverage on Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on Potential neurotoxicity associated with methotrexate - Nature

Potential neurotoxicity associated with methotrexate  Nature

Potential neurotoxicity associated with methotrexate - Nature

Click here to get full coverage on Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis - PR Newswire

Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis  PR Newswire

Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis - PR Newswire

Click here to get full coverage on MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days - Yahoo Finance

MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days  Yahoo Finance

MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days - Yahoo Finance

Click here to get full coverage on Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome | Communications Biology - Nature

Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome | Communications Biology  Nature

Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome | Communications Biology - Nature

Click here to get full coverage on 40,388 Shares in Minerals Technologies Inc. (NYSE:MTX) Purchased by Jefferies Financial Group Inc. - MarketBeat

40,388 Shares in Minerals Technologies Inc. (NYSE:MTX) Purchased by Jefferies Financial Group Inc.  MarketBeat

40,388 Shares in Minerals Technologies Inc. (NYSE:MTX) Purchased by Jefferies Financial Group Inc. - MarketBeat

Click here to get full coverage on Emails show Missouri leader pleads with vendors to fix childcare payment system problems - Missourinet

Emails show Missouri leader pleads with vendors to fix childcare payment system problems  Missourinet

Emails show Missouri leader pleads with vendors to fix childcare payment system problems - Missourinet

Click here to get full coverage on New Analyst Forecast: $MTX Given $92.0 Price Target - Nasdaq

New Analyst Forecast: $MTX Given $92.0 Price Target  Nasdaq

New Analyst Forecast: $MTX Given $92.0 Price Target - Nasdaq

Click here to get full coverage on Figure 3. Expression of mDHFR-mRuby is commensurate to the... - researchgate.net

Figure 3. Expression of mDHFR-mRuby is commensurate to the...  researchgate.net

Figure 3. Expression of mDHFR-mRuby is commensurate to the... - researchgate.net

Click here to get full coverage on A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Nature

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance  Nature

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Nature

Click here to get full coverage on High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights - Frontiers

High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights  Frontiers

High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights - Frontiers

Click here to get full coverage on MTX Group Acquires Stralto - FinSMEs

MTX Group Acquires Stralto - FinSMEs

Click here to get full coverage on "Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind - GamesRadar+

"Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind  GamesRadar+

"Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind - GamesRadar+

Click here to get full coverage on Morphology and proliferation of HT29-MTX cells under static and dynamic... - researchgate.net

Morphology and proliferation of HT29-MTX cells under static and dynamic...  researchgate.net

Morphology and proliferation of HT29-MTX cells under static and dynamic... - researchgate.net

Click here to get full coverage on MTU Aero Engines AG (ETR:MTX) Not Lagging Industry On Growth Or Pricing - simplywall.st

MTU Aero Engines AG (ETR:MTX) Not Lagging Industry On Growth Or Pricing  simplywall.st

MTU Aero Engines AG (ETR:MTX) Not Lagging Industry On Growth Or Pricing - simplywall.st

Click here to get full coverage on Where are the Opportunities in (MTX) - news.stocktradersdaily.com

Where are the Opportunities in (MTX)  news.stocktradersdaily.com

Where are the Opportunities in (MTX) - news.stocktradersdaily.com

Click here to get full coverage on Synthesis of MTX by the reaction between metal salt of... - researchgate.net

Synthesis of MTX by the reaction between metal salt of...  researchgate.net

Synthesis of MTX by the reaction between metal salt of... - researchgate.net

Click here to get full coverage on PolyNovo Secures TGA Clearance for NovoSorb MTX in Australia - TipRanks

PolyNovo Secures TGA Clearance for NovoSorb MTX in Australia  TipRanks

PolyNovo Secures TGA Clearance for NovoSorb MTX in Australia - TipRanks

Click here to get full coverage on Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis - BioSpace

Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis  BioSpace

Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis - BioSpace

Click here to get full coverage on The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter - The New York Times

The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter  The New York Times

The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter - The New York Times

Click here to get full coverage on (A) Graphical representation of the mito-QC construct (mtx-QCXL). A... - researchgate.net

(A) Graphical representation of the mito-QC construct (mtx-QCXL). A...  researchgate.net

(A) Graphical representation of the mito-QC construct (mtx-QCXL). A... - researchgate.net

Click here to get full coverage on Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial - Nature

Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial  Nature

Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial - Nature

Click here to get full coverage on MTX 2026 - HTX | Home Team Science and Technology Agency

MTX 2026  HTX | Home Team Science and Technology Agency

MTX 2026 - HTX | Home Team Science and Technology Agency

Click here to get full coverage on Bitcoin Cash Vs Bitcoin: Investors Guide and Mantix (MTX) Innovation Re-Shapes The Crypto Market Forever - Mid-day

Bitcoin Cash Vs Bitcoin: Investors Guide and Mantix (MTX) Innovation Re-Shapes The Crypto Market Forever  Mid-day

Bitcoin Cash Vs Bitcoin: Investors Guide and Mantix (MTX) Innovation Re-Shapes The Crypto Market Forever - Mid-day

Click here to get full coverage on PHOTOS: MTX Auto Club wins 10 trophies at 105Gu car show | Multimedia | guampdn.com - guampdn.com

PHOTOS: MTX Auto Club wins 10 trophies at 105Gu car show | Multimedia | guampdn.com  guampdn.com

PHOTOS: MTX Auto Club wins 10 trophies at 105Gu car show | Multimedia | guampdn.com - guampdn.com

Click here to get full coverage on An In Vitro Study of the Effects of Methotrexate Loaded Biocomposite Beads on MG63 Osteoblast Cells - Nature

An In Vitro Study of the Effects of Methotrexate Loaded Biocomposite Beads on MG63 Osteoblast Cells  Nature

Minerals Technologies Inc (MTX)

Price Chart

Key Statistics

Technicals

About MTX

Latest News

Mediar commences dosing in Phase II trial of MTX-463 for IPF - Clinical Trials Arena

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis - PR Newswire

Short Interest in Minerals Technologies Inc. (NYSE:MTX) Rises By 19.0% - MarketBeat

Advanced Charts

Top Gainers

Top Losers